Abbreviations {#nomen0010}
=============

CoVs

:   Coronavirus

COVID-19

:   Coronavirus Disease 2019

E

:   Envelope protein

hDPP-4

:   Human Dipeptidyl Pentidase-4

HIV

:   Human Immunodeficiency Virus

LPV

:   Lopinavir

M

:   Membrane protein;MAVS,O-mitochondrial antiviral signalling protein

MERS-CoVs

:   Middle East Respiratory syndrome coronavirus

N

:   Nucleoprotein

NOX2

:   nicotinamide adenine dinucleotide phosphate hydrogen oxidase 2

nsp-3

:   Non-structural protein-3

RBD

:   Receptor Binding Domain

RNA

:   Ribonucleic Acid

S

:   Spike protein

SARS

:   Severe Acute Respiratory Syndrome

URT

:   Upper Respiratory Tract

VLPs

:   Virions Like Particles

WHO

:   World Health Organization

RT-PCR

:   Reverse transcription polymerase chain reaction

1. Introduction {#sec1}
===============

Though research on coronavirus disease 2019 (COVID-19) was going on at global level since last two decades, highly virulent transmission of COVID-19 came into existence as highly fatal human pathogen during June 2012 in Arabian Peninsula ([@bib20]). At that time, it was christened as Middle East Respiratory Syndrome Coronavirus (MERS-CoVs). Corona virus is an enveloped, positive sense ribonucleic acid (RNA) virus found in various species mainly in mammals and birds ([@bib73]). The World Health Organization (WHO) named the coronavirus (CoVs) as severe acute respiratory syndrome coronavirus-2(SARS-CoV-2) recently.

The components of SARS-CoV-2 are spike glycoprotein (S), membrane protein (M), nucleocapsid protein (N) and envelope protein (E). The spikes present on the virus consist of a single-pass trans membrane anchor, a large ectodomain and short intracellular tail. The ecto domain contains two subunits S1 and S2 ([@bib75]). The homo trimers of S-protein help in building of spikes on the viral surface which play a key role in its attachment with host receptors ([@bib12]; [@bib39]). The M glycoprotein performs three major functions i.e. it provides shape to the virions, aids in promoting curvature of membrane, and facilitates binding to the nucleocapsid ([@bib86]; [@bib105]). The E-glycoprotein plays a key role in the assembly and pathogenesis of virus ([@bib38]; [@bib107]). The N- glycoprotein consists of two domains which bind to the RNA genome of the virion. It is also believed that N-glycoprotein bind stonon-structural protein 3 (nsp-3) which, in turn helps in tying the genome to replication-transcription complexes (RTCs) and helps in packaging of enfolded genome into virions ([@bib27]; [@bib49]; [@bib61]). The structure of SARS-CoV-2 is shown in [Fig. 1](#fig1){ref-type="fig"} .Fig. 1Structure of SARS-CoV-2. SARS-CoV-2 binds with ACE-2 receptor and influxes host cells through receptor-mediated endocytosis. Inside the cell, SARS-CoV-2 forms a layer called capsid vesicle. Microtubules transport viruses to the cytoplasm. Viral RNA is involved in transcription process in the cytoplasm and conversion into viral genome mRNA. It also affects translation processes and develops viral protein. Viral RNA and viral proteins form new viruses. Thus virus multiplies and forms capsulated nucleoprotein. The multiplied viruses cause apoptosis in the cell and affect other cells also ([@bib18]).Fig. 1

2. Symptomatic features of COVID-19 {#sec2}
===================================

The main symptoms of COVID-19 include runny nose, sneezing, common cold, cough, confusion, myalgia, diarrhea, vomiting, shortness of breath, wheezing and fever ([@bib87]; [@bib154]).The virus enters the respiratory tract through nose and stays there for three days. Afterwards, it starts infecting upper respiratory tract (URT) with above-mentioned symptoms. COVID-19 causes URT illness including acute exacerbation of chronic obstructive pulmonary disease, bronchitis and pneumonia, with co-morbidities in digestive, cardiac ([@bib163]), renal ([@bib30]) and circulatory systems as well ([@bib59]).

The risk factor for COVID-19 infection is higher in both infants as well as in geriatric age group. Also, diabetic patients are more prone to COVID-19 with higher rate of mortality and co-morbidity. The risk factors associated with the COVID-19 are obesity, smoking, low blood pressure, impaired gas exchange, leukopenia, anemia, disturbance in liver and kidney functions etc.

3. Life cycle of SARS-CoV-2 in host cell {#sec3}
========================================

The life cycle of COVID-19 begins when virion enters the host and gets attached to the host cells by interaction between glycoprotein "S" and host receptors human angiotensin converting enzyme-2 (ACE-2) leading to tropism of virus. The virion enters the cytosol with the help of capthesin and transmembrane protease, serine 2 (TMPRSS2) which results in cleavage of "S" protein from two sites ([@bib57]). The first cleavage helps in separation of receptor binding domains (RBD) and fusion domain of "S" protein while second cleavage exposes fusion peptides to endosomes. Six helical bundles are formed, which release virions into the cytoplasm. After attachment, the replication cycle begins, during which, translation of replica gene in virion genomic RNA takes place. This is encoded by two large open reading frames ORF1a and ORF1b that give rise to poly protein 1a and 1b (pp1a and pp1b) and are expressed by slippery sequence ^'^5UUU AAC-3^\'^and RNA pseudo-knot.This results in ribosomal shifting and stops the ribosomal elongation. It also acts as mRNA for expression of structural and accessory proteins. Finally, virus spreads to different parts of the body. During this phase, "S1", "M" and "E" are translated, which help the virion to enter into endoplasmic reticulum and endoplasmic reticulum-golgi intermediate compartments. "M" leads to protein-protein interaction, which further combines with "E" to activate virus-like particles (VLPs), which in turn, lead to formation of corona envelope. Then "N" protein promotes formation of VLPs and fusion of encapsidate with endoplasmic reticulum golgi intermediate compartment (ERGIC) ([@bib141]).This gives rise to assembly of COVID-19. The exocytosis of virions takes place as a result of interaction between normal and affected cells. Finally the giant cells are formed and virus spreads to other cells ([@bib8]) ([Fig. 2](#fig2){ref-type="fig"} ).Fig. 2Viral cycle of SARS-CoV-2 in target host cell and target drug.Fig. 2

4. Diagnosis of COVID-19 infection {#sec4}
==================================

The detection of SARS-CoV-2 is done by performing antibody testing such as enzyme-linked immune sorbent assay (ELISA) for Immunoglobulin G(IgG), and Immunoglobulin A (IgA) or plaque reduction neutralization test (PRNT) in blood or airways fluid ([Fig. 3](#fig3){ref-type="fig"} ). Distal lung sampling results in its satisfactory diagnosis ([@bib18]; [@bib110]). SARS-CoV-2 kits are very important tools for easy and fast diagnosis in coronavirus pandemic. Various biopharmaceutical companies are working on virus kit research and development. Various kits made by different countries are mentioned in [Table 1](#tbl1){ref-type="table"} .Fig. 3Tests used for diagnosis of SARS-CoV-2 infection.Fig. 3Table 1Diagnostic kits used to detect SARS-CoV-2 infection.Table 1Sr. No.PathokitCountryReference1.GenMarkDx -- Multiplex DiagnosticsCanada([@bib146])2.XCR Diagnostics -- Quantitative Polymerase Chain Reaction (qPCRUnited states of America3.SensDx -- Ultrasensitive ElectrodesPoland4.Aperiomics -- Deep Metagenomic SequencingUnited states of America5.MiRXES -- MicroRNA DiagnosticsSingapore6.Truenat Beta CoV testIndia([@bib62])

4.1. Real time reverse transcription polymer chain reaction (RT-PCR) {#sec4.1}
--------------------------------------------------------------------

It is the most widely used nuclear derived method to detect the genetic material present in the pathogen. In this technique, radioactive isotope markers were conventionally used to identify the desired target genetic material. But now a days these radioactive isotopes are being replaced by fluorescent dyes. In RT-PCR, the sample is taken mainly from the patient\'s throat and nose. The collected sample is treated with solvents to remove fats and proteins and extract only RNA. The obtained RNA consists of mixture of infected person\'s genetic material as well as coronavirus RNA. Then the RNA is reverse transcribed to DNA with help of enzymes. Additional short fragments of DNA that are complementary to specific parts of the transcribed viral DNA are then added. The added fragments attach to the target site of viral DNA if sample consists of virus. The added genetic material acts as a builder for DNA strands during amplification, while the labels added help in detecting the virus. The mixture is then placed under the RT-PCR machine. The machine cycles through heating and cooling of sample so that chemical reaction takes place and forms new copies of viral DNA. These cycles take place 35 times, so that at the end of the cycle, about 35 billion identical copies of viral DNA formed. The fluorescence emission by sample is measured by machine and helps in assessing presence or absence of virus ([@bib67]).

4.2. Computed tomography (CT) imaging {#sec4.2}
-------------------------------------

It has been found that chest CT imaging is more steady, practical and expeditious technique to diagnose and assess COVID-19. In some of the studies, it has been found that computed tomography is more sensitive tool than RT-PCR to assess COVID-19. The sensitivity of CT and RT-PCR was reported to be 98% and 71% respectively ([@bib65]). Ai et. al., 2020, studied the comparison between RT-PCR and chest CT for the diagnosis of COVID-19. In the study total 1014 patients underwent RT-PCR and chest CT. The results revealed that out of 1014 patients, 601 (59%) showed positive results with RT-PCR while 888 (88%) patients showed positive CT scans results. So, it was concluded that chest CT is more reliable technique for the diagnosis of COVID-19 ([@bib5]; [@bib7]).

5. Treatment strategies {#sec5}
=======================

With the prevalence of COVID-19 reaching a new hight every day, there is an immediate need to find safe and efficacious measures to diagnose, treat, mitigate and combat the disease. Looking at the alarming dimensions that the disease is acquiring, treatment strategies among various systems of medicines are being investigated. Based on the treatments offered so far and clinical findings, the treatment strategies can be categorized into three classes.

5.1. Synthetic drugs {#sec5.1}
--------------------

Antibiotics, for obvious reasons, are not expected be effective in the treatment and a combination of antiviral drugs is being used. Studies also confirm that flu shots are not efficient in the fight against COVID-19 as the patients continue to suffer despite the treatment ([@bib160]). In the meantime, Thai health officials claimed to have successfully handled the infection with acocktail of antiviral drugs that include lopinavir and ritonavir under the name "*Kaetra*" along with flu medication oseltamivir. However, a lot more studies need to be conducted to declare this combination as a treatment for COVID-19. Randomized clinical trials using combination of antiviral drugs are already being conducted ([@bib60]). Triple combination of interferon beta-1b, lopinavir--ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 has been tried. The possibility of successful treatment exists because the same combination was successfully used to treat SARS outbreak in 2002 and SARS-CoV-2 is reported to be a strain similar to the earlier one with the genomic sequence of COVID-19 being about 75--80% similar to that of SARS. Lopinavir was used as major antiviral drug to treat during the SARS outbreak. Lopinavir has been reported to treat COVID-19 ([@bib8]),([@bib8]). However, its efficiency to mitigate COVID-19 is yet to be fully established. To analyze antiviral effect of inferferon-α2b (IFN- α2b) and ribavirin, SARS-CoV-2 was isolated from hCoV-Emc/2012 replication process by Vero and LLC-MK2 cells. Combination of IFN- α2b and ribavirin achieved comparable remission in low concentration. As per [@bib44], combination of IFN- α2b and ribavirin may also prove to be useful ([@bib44]). Anti-ebola and anti-HIV drugs combination (remdesivir + galidesivir) showed significant action against the enzymes responsible for virus replication. These drugs have been able to alleviate the symptoms of COVID-19 similar to that in SARS and MERS ([@bib76]). In an *invitro* cell line study, this drug also showed very good antiviral effect ([@bib156]).

The Gilead biotechnology company, USA reported preclinical trials of Remdesivir (a nucleotide analogue) which led to remission in animal models ([@bib140]). Later, it was reported to be effective in the treatment of COVID-19 patients also ([@bib58]). Another study, conducted on 760 patients in placebo-controlled trials also proved the effectiveness of remdesivir. This drug has now received emergency use authorization by USFDA on 1st May 2020 ([@bib45]).

Frequently used antimalarial drug, Chloroquine (CQ) and Hydroxychloroquine (HCQ) have also been explored and found to be quite effective against COVID-19 ([@bib156]). CQ and HCQ increase endosomal pH and interfere with the glycosylation of cellular receptor of SARS-CoV-2. Thereby they have the potential to block viral infection ([@bib156]). Moreover, they change the pH of lysosomes and likely inhibit cathepsins, that leads to the formation of the autophagosome which cleaves SARS-CoV-2 spike protein. It is also reported that CQ and HCQ through the inhibition of MAP-kinase interfere with SARS-CoV-2 molecular crosstalk, besides altering the virion assembly, budding and interfering with the proteolytic processing of the M protein. It is reported that they interfere with ACE-2 receptor\'s glycosylation. Since, SARS-CoV-2 utilizes the similar surface receptor ACE-2, it is believed that CQ and HCQ can also thus prevent SARS-CoV-2 attachment to the target cells ([@bib164]). Some studies have also been initiated and showed very good effect of CQ and HCQ against SARS-CoV-2 ([@bib55]; [@bib142]).; [@bib54]; ([@bib83]). However, due to reported potential clinical toxicity issues such as retinal toxicity, the use of CQ and HCQ is not recommended by WHO.

An antiviral drug favipiravir (Avigan), got approval in Japan in 2014. In 2016, this drug was used as an emergency aid for the Ebola virus outbreak. A clinical trial involving 80 participants (in Shenzhen city) demonstrated chest symptoms improvement in patients of COVID-19 treated with favipiravir. The drug was able to shorten the recovery time from 11 days to 4 days in mild and regular cases. Another trial showed that the drug shortened fever duration from an average of 4.2 days--2.5 days. Favipiravir has been reported to be effective, without any obvious side-effects, in helping coronavirus patients recovery. In another study carried out in China, two mild and two severe COVID-19 associated pneumonia patients were treated with combined Western and Chinese medicine treatment (Lopinavir/ritonavir/arbidol/ShufengJiedu Capsule). Three of the four patients showed significant improvement in pneumonia associated symptoms. The remaining patient with severe pneumonia showed signs of improvement; however, the efficacy of this combination treatment warrants further investigation ([@bib88]).

In a recent study, Rho kinase (ROCK) inhibitor, Fasudil has been explored to treat COVID-19. In patients with COVID-19, activation of ROCK causes burst in inflammatory features, immune cell migration, apoptosis, coagulation, contraction, and cell adhesion in pulmonary endothelial cells, leading to endothelium barrier dysfunction and edema as hallmarks of lung injury. Fasudil attenuates this effect due to its excellent anti fibrotic activity ([@bib2]). It has been found that angiotensin-converting enzyme-2 (ACE-2) is the receptor required for the cellular entry of SARS-CoV-2 ([@bib57]). Envelope spike protein of SARS-CoV-2 mediates its attachment and fusion into the human cells through binding ACE-2 with super-affinity and efficiency. ACE-2 is widely expressed in alveolar epithelial cells and converts angiotensin 2 to angiotensin (1--7). Angiotensin 2 triggers a number of adverse effects like interstitial fibrosis, increased coagulation, interference with adaptive immunity by activating macrophages and other cells of the immune system, with consequent increased production of IL-6, TNFα and other inflammatory cytokines. ROCK inhibitors upregulate the axis of ACE-2, and are thereby found effective in treating COVID-19.

In one of the studies, a 53-year-old woman suffering from COVID-19 was treated with a combination of moxifloxacin and oseltamivir. She was treated with moxifloxacin 400 mg intravenously once a day for eight days and antiviral drug oseltamivir 75 mg orally twice a day for 5 days. After seven days treatment, patient\'s symptoms got reduced and she tested negative ([@bib41]).

In recent clinical studies the use of steroidal drug Dexamethasone has been very effective to treat patients suffering from COVID-19. It easily diffuses through the host cell membranes and bind to the glucocorticoid receptor in the cell cytoplasm. This receptor binding triggers a cascade of reactions that end up [suppressing](https://www.ncbi.nlm.nih.gov/books/NBK531462/){#intref0045} pro-inflammatory cytokines IL-1, IL-2, IL-6, IL-8, TNF, and IFN-gamma and reduce the severity of Covid-19. Dexamethasone also inhibits the overaction of macrophages in patients suffering from COVID-19. A British research team found that Dexamethasone\'s (2 mg tablet) effect was most striking among patients on ventilators. Those [@bib157] were receiving oxygen therapy but were not on ventilators also saw improvement: their risk of dying was reduced by 20%. The steroid had no effect on people with less severe cases of COVID-19 --- those not receiving oxygen or ventilation ([@bib72]).

[Table 2](#tbl2){ref-type="table"} summarizes various antiviral drugs which may have potential to treat COVID-19 with their mechanism of action. [Table 3](#tbl3){ref-type="table"} summarizes possible drugs with dose to mitigate COVID -19 and [Table 4](#tbl4){ref-type="table"} provides update about recent clinical trials on COVID-19 with possible targets.Table 2Various antiviral drugs and their mechanism of action.Table 2VirusDrugMechanism of actionReferenceEbolamAb114[@bib132]HIVZidovudineNucleoside reverse transcriptase Inhibitor[@bib69]NevirapineNonnucleoside reverse transcriptase Inhibitor[@bib68]RitonavirProtease inhibitor[@bib28]EnfuvirtideEntry (Fusion) inhibitor[@bib158]RaltegravirIntegrase inhibitor[@bib149]MaravirocCCR5 receptor inhibitor[@bib9]SARS- CoVsRibavirinDecrease intracellular guanosine triphosphate which results in inhibition of caps of viral transcripts, suppress cellular and humoral immune response([@bib26]; [@bib112])Lopinavir (LPV) + Ritonavir (R)R helps in inhibiting CYP3A4 metabolism of LPV and increased LPV serum conc.[@bib31]MethylprednisoloneHelp in decreasing cytokine storm (ILs, and TNF)[@bib143]ZIKAChloroquineInhibitory effect against early stages of ZIKA Virus in mice[@bib78]\
[@bib40]Table 3List of drugs that have been used to mitigate COVID -19.Table 3S.N.DrugsBrand NameManufacturerDoseDuration of treatmentReferences1.Lopinavir/ritonavirAluvia®ABBOTT health care Pvt. Ltd.50 mg/20 0 mg in tablet formNot more than 10 days[@bib42]2.RibavirinRebetol, Ribasphere, Copegus and VirazoleValeant Pharmaceuticals500 mg thrice a day or given in combination with ritonavir/Lopinavir and INF-α through Intravenous infusionNot more than 10 days[@bib42]3.Chloroquine phosphateAralenNovartis, Mylan and Teva500 mg, 250 mg twice a day given orallyNot more than 10 days[@bib42]4.UmifenovirArbidolPharmastandart50 mg, 200 mg thrice a day in oral formNot more than 10 days[@bib42]5.OseltamivirANTIFLU capCipla75 mg twice in a day in oral form3--14 days([@bib56])6.UmifenovirArbidolPharmastandart0.2 g three times a dayNot more than 14 days[@bib165]7.BaricitinibOlumiantEli Lilly2 mg once dailyNot more than 14 days([@bib128], [@bib129]; [@bib148])8.BromhexineBROLYTAlco Pharma Ltd.4 mg and 8 mg three times a day--[@bib133]9.FingolimodGilenyaNovartis0.5 mg once in a dayNot more than 3 days([@bib92])10.BevacizumabAvastinAsparÂ Pharmaceuticals500 mg--([@bib91])11.PirfenidoneEsbrietGlenmark Pharmaceuticals267 mg three times a day--([@bib93])12.ThalidomideThalomidGrunenthal100 mgNot more than 14 days([@bib90])Table 4Clinical trials on COVID-19.Table 4Sr. No.DrugNo. of PatientsMechanismClinical TrialsOutcomesReferences1.Chloroquine phosphate100Increase endosomal pH which is required for fusion of virus and cells, also interfere with the glycosylation of cellular receptors of SARS-CoVs. ChiCTR2000029939\
. ChiCTR2000029760\
. C hiCTR2000029609\
. C hiCTR2000029761\
.ChiCTR2000029837\
. C h iCTR2000029 9\
. Chi CTR2000029826\
. ChiCTR2000029803*In-vitro* studies reveal that drug block the virus at micro molar concentration with half-cytotoxic concentration (CC50) greater than 100 μM and half-maximal effective concentration (EC50) of 1.13 μM. Drug also improved symptoms of pneumonia in COVID-19 patients[@bib54]2.Shuanghuanglian oral liquid (SHL)3Mast cells stabilization by activation of mitochondrial calcium uniporterChiCTR2000029605Treated patients with COVID-19 but further clinical trials are required to evaluate its efficacy against COVID-19([@bib53]; [@bib106])3.Hydroxychloroquine + Azithromycin36Hydroxyl chloroquine inhibit toll like receptors and stops dentric cell activation and result in antiinflammatory response while azithromycin inhibits protein synthesis (50S) and inhibits translation process in MrnaOpen-label non-randomized clinical trialHydroxychloroquine (600 mg) helped in combating COVID-19 and addition of azithromycin synergesis the effect[@bib55]4CamostatMesilate + Hydroxychloroquine334CamostatMesilate inhibits serine protease TMPRSS2 while Hydroxychloroquine interrupt the viral entry and replication through glycation of ACE2 receptotorsRandomizedOngoing trials([@bib99])5Favipiravir100inhibits RNA polymeraseRandomizedOngoing trials([@bib97])6.Clevudine60Inhibiting the replication of viral genetic materialsRandomizedOngoing trials([@bib102])7.Desferal50Inhibits human cytomegalovirus replicationRandomizedOngoing trials([@bib33]; [@bib138])8.Losartan50decreases activation of nuclear factor kappa B and mitogen-activated protein kinasesInterventionalOngoing trials([@bib48]; [@bib135])9.Ruxolitinib80Lower the hyperinflammation caused by the virusInterventionalOngoing trials([@bib103])10.Baricitinib80Lower the hyperinflammation caused by the virusInterventionalOngoing trials([@bib100])11.Dapagliflozin900SGLT-2 InhibitorsRandomizedOngoing trials[@bib70]12.Tocilizumab400IL-6 inhibitorInterventionalOngoing trials[@bib114]13.Ciclesonide141blocks coronavirus RNA replication by targeting viral NSP15RandomizedOngoing trials([@bib96])Others1.Convalescent Plasma55--InterventionalOngoing trials([@bib101])2.BCG Vaccine700--InterventionalOngoing trials([@bib104])

5.2. Phytochemicals {#sec5.2}
-------------------

Saikosaponins are triterpene glycosides isolated from medicinal plants like *Bupleurum* *spp, Heteromorpha* *spp and Scrophularia scorodonia* which possess potent antiviral activity ([@bib77]). Extracts belonging to *Lindera* *aggregata, Lycoris* *radiata, Artemisia annua and Pyrrosia lingua* have been recorded to show antiviral activity especially against SARS. An Amentoflavone isolated from *Torrey* *a* *nucifera* (belonging to the family Taxaceae), a native of southern Japan and South Korea has been shown to inhibit SARS-CoV 3 CL protease. *Isatis* *tinctoria,* known as *Asp of Jerusalem* belonging to the family Brassicaceae, has been shown to have SARS-CoV 3CL protease inhibition acivity ([@bib79]). With 99% of small molecules failing to be effective, it remains to be seen what can be used in the fight against COVID-19. [Fig. 4](#fig4){ref-type="fig"} exhibits the patents granted on drugs and small molecules which might be effective against COVID-19.Fig. 4Number of patents granted to drugs and small molecules having potential to treat COVID-2019.Fig. 4

Lianhuaqingwen (LH) is a traditional Chinese medicine that has been used previously to combat SARS, influenza virus and enhance immunomodulatory effects. [@bib166], studied the antiviral and anti-inflammatory effect of LH against SARS-CoV-2. In this study, African green monkey\'s kidney epithelial cell (Vero E6 cells) was used as an *in* *vitro* cell line. The cytopathic effect (CPE) and plaque reduction assay was used to assess the antiviral activity of LH in Vero E6 cells. The results revealed that the LH helped in inhibition of SARS-CoV-2 replication. It has been also found that LH showed significant reduction in pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrotic factor-α (TNF- α) and chemokine (C--C motif) ligand 2/monocyte chemo attractant protein 1 (CCL2/MCP-1).

5.3. Vaccines {#sec5.3}
-------------

In 1986, US patent (US 4567043A) was granted for Canine Corona vaccine which on parenteral administration provided humoral protection from virulent canine corona virus that mostly affect the intestinal tract of dogs ([@bib3]). A novel vaccine was developed using cDNA that is encoded with structural antigens such as spike (S) protein, membrane (M) protein, envelope (E) protein and nucleocapsid (N) protein for SARS caused by COVID-19. Among the developed vaccines, (M) and (N) DNA vaccines showed cytotoxic T Lymphocytes (CTL) activity and human T-cell proliferation in SCID-PBL/hu mice and in vivo human model ([@bib111]). Recently, a new strategy has been developed based on the immunogenetics and immunogenomics. Molecular docking technique was employed for predicting the combination effect of B- and T-cell epitope on the nonstructural protein 4 coronavirus. To target the virus, two peptide sequences from the nonstructural protein 4 of beta coronavirus (IRNTTNPSAR and PTDTYTSVYLGKFRG) were selected and were found to be potent T-cell epitopes. They were found to interact perfectly with epitope grooves of major histocompatibility complex (MHC) allelic protein (HLA-A\*01:01 and HLA-DRB5\*01:01) that formed a stable MHC complex. It can, therefore, be considered as potential peptide for development of peptide based corona virus vaccine ([@bib11]). In another study, computational approach along with bioinformatics tools was adopted for vaccine design. Based on the docking score as well as antigencity scores, natural inhibitors such as tanshinoneIia and methyl tanshinonate were identified as effective drugs and FVFLVLLPL (MHC class-I allele) and FVFLVLLPL(MHC class-II allele) were selected as best antigenic epitope respectively for vaccine design ([@bib71]). Recently, US developed a vaccine and started first human trial (Phase 1 trial) in healthy human volunteers to monitor the desired responses in human immune system along with safety profile. The trial has enrolled 45 healthy volunteers for a period of 6 weeks. The vaccine is based on "messenger RNA vaccine platform technology". The experience on previous MERS vaccine development for targeting the surface protein of virus led to the idea of this vaccine ([@bib130]). Out of the two vaccines, REGN 3048 and REGN 3051, manufactured by Regeneron, USA, were able to more keenly bind to viruses resulting in possibility of developing antibodies. Vaccine REGN 3048 was found to be ineffective against COVID-19, however the company is retesting it for the possible effects against COVID-19 ([@bib89]). The traditional immunization technique of using live attenuated or inactivated viruses has been reported with drawback of leaving the recipient sick again. The use of genetic coding technology in the development of new vaccine development can assure safety over the traditional immunization technique.

Bacille Calmette-Guérin (BCG) is a live attenuated strain of mycobacterium bovis used against tuberculosis and leprosy ([@bib157]). Vaccine repositioning indicated its potential use against multiple sclerosis, reducing blood sugar levels in type-1 diabetes and also in various types of cancer like non-Hodgkin\'s lymphoma and bladder cancer. It demonstrates a non-specific effect and thus its use may prove to be favorable against viral pathogens as well ([@bib85]). A study reported that oral zinc sulphate being an effective immunomodulator can be combined with BCG vaccine to provide protection against COVID-19 ([@bib139]). The outcomes of the ongoing randomized trials (phase III) of BCG vaccine are eagerly anticipated ([@bib95]);([@bib94]).

[Table 5](#tbl5){ref-type="table"} compiles the patents on vaccines having therapeutic potential to treat COVID-19 while [Table 6](#tbl6){ref-type="table"} summarizes the trials going on across the globe for the development of drugs and vaccines for the treatment of COVID-19.Table 5Existing patented vaccines that have been repurposed to treat COVID-19.Table 5Sr. No.VaccinePublicationPatent NumberPatent DateTargeted siteObservationReference1.Live attenuated corona virus vaccinesUnited State Patent ApplicationUS20060039926Feb 23, 2006Orf1a/polyprotein (p59/nsp14/ExoN)MHV virus showed reduction of replication in mice at 5^th^ day with intracerebral inoculation([@bib155])2.DNA based vaccinesInternationalWO20050817169 Sept 2005calreticulin−nucleocapsid fusionResulted in potent nucleocapsid-specific humoral and T cell-mediated immune responses([@bib161])3.Protein-Based Vaccines.InternationalWO2010063685June 10, 2010S-Trimer subunit, ACE2\
ReceptorO/W emulsion helped to treat SARS-CoVs by neutralizing antibody responses in animal models[@bib10]4.Virus-like Particle VaccinesInternationalWO201504237319 Sept 2014S proteinThe Sera (SAB-300 or SAB-301) were injected into Ad5-hDPP4 transduced BALB/c mice, which protected mice against MERS-COVs[@bib144]5.mRNA-Based Vaccines.InternationalWO2017070626April 27, 2017mRNA-1273Intradermal administration of a lipid nanoparticle (LNP)-encapsulated mRNA\
mixture encoding MERS-CoVs S proteins into mice resulted in translation in vivo and induction of humoral immune responses[@bib32]Table 6Summary of the research projects currently ongoing for the development of drugs and vaccine against COVID-19.Table 6Institute name/CollaborationDrug NameReferenceI-MabBiopharmaTJM2[@bib66]MedicagoVirus Like Particle (unnamed)([@bib81])Airway Therapeuticsrecombinant protein named AT-100([@bib124])Tiziana Life SciencesTZLS-501([@bib80])OyaGenOYA1([@bib145])BeyondSpringBPI-002([@bib152])AltimmuneUnnamed intranasal coronavirus vaccine([@bib13])Inovio PharmaceuticalsINO-4700([@bib52])Inovio Pharmaceuticals and Beijing Advaccine BiotechnologyINO-4800([@bib52])Algernon PharmaceuticalsNP-120 (Ifenprodil)([@bib117])University of British Columbia and APEIRON BiologicsAPN01([@bib34])National Institute of Allergy and Infectious DiseasesmRNA-1273 vaccine([@bib136])MIGAL Research InstituteInfectious Bronchitis Virus (IBV) vaccine([@bib82])Tonix PharmaceuticalsTNX-1800([@bib119])Innovation PharmaceuticalsBrilacidin([@bib15])Clover BiopharmaceuticalsA recombinant subunit vaccine([@bib121])VaxartOral recombinant vaccine (unnamed)([@bib123])CytoDynLeronlimab([@bib36])LineaRx and Takis BiotechLinear DNA Vaccine([@bib4])BioxytranBXT-25([@bib115])NovavaxMERS CoV vaccine([@bib108])Gilead SciencesRemdesivir (GS-5734)([@bib147])RocheActemra([@bib118])BiocrystPharmaGalidesivir([@bib137])Lattice BiologicsAmnioBoost([@bib116])PfizerUnnamed([@bib1])ZydusCadilaUnnamed DNA Vaccine([@bib52])Biogen and Vir BiotechnologyMonoclonal antibodies([@bib151])Genentech (Roche group)Actemra® (tocilizumab)([@bib52])

5.4. Role of nutraceuticals in RNA virus infection {#sec5.4}
--------------------------------------------------

Certain nutraceuticals have also shown efficacy in combating COVID-19. Their mechanisms are discussed here. Viral toll-like receptor (TLR7) of COVID-19 is responsible to trigger hydrogen peroxide generation within the alveolar macrophages via nicotinamide adenine dinucleotide phosphate hydrogen oxidase 2 (NOX2) activation which oxidizes Cys98 on TLR7. Such oxidation blocks receptor potential to conduct signals for type 1 interferon production. Nutraceuticals having potential to inhibit NOX2, superoxide generation or preventing oxidation of Cys98 in TLR7 have potential to evoke TLR7 mediated type 1 interferon production towards RNA virus infections including COVID-19. RNA virus infections have been shown to induce O-GlcNacylation of mitochondrial antiviral signalling protein (MAVS) at multiple sites which prohibits its susceptibity for K63-linked ubiquitination and further interferon regulatory factor 3 (IRF3) activation. Glucosamine supplementation has been investigated to upregulate MAVS to activate IRF3 in response to viral infections. Currently, vitamin C infusion is under clinical trial for the treatment of severe COVID-19 virus infected pneumonia as it plays important role in reducing inflammatory response and has antioxidant property. Vitamin C has earlier been reported to prevent neutrophil accumulation, alveolar fluid and cytokine surge caused by sepsis ([@bib113]).

The US-FDA has recently issued certain guidelines pertaining to the ongoing clinical trials for the development of medicinal products. Impact on the conduct of clinical trials of medical products is anticipated since challenges may arise from quarantines, site closures, travel limitations, interruptions to the supply chain for the investigational product, or other considerations if site personnel or trial subjects become infected with COVID-19 ([@bib46]).

5.5. Convalescent plasma therapy {#sec5.5}
--------------------------------

Plasma therapy can reduce the mortality rate of COVID-19 ([@bib37]). In this therapy, convalescent plasma or immunoglobulins administrated to the patients [@bib157] are suffering with COVID-19. This therapy can enhance the immunity of the patients ([@bib19]). In one of the studies in 2014, convalescent plasma therapy was used for the treatment of Ebola virus. It was recommended by WHO ([@bib29]). The Indian Council of Medical Research (ICMR) has approved first clinical trials for convalescent plasma therapy in SVP Hospital, Ahmedabad, India. ([@bib153].in/news/india/2020/04/19/gujarat-to-start-clinical-trial-with-convalescent-plasma-therapy-for-covid-19.html). FDA is also working on development of convalescent plasma therapy. They provided guidance in mentions about patient eligibility, investigation pathways of convalescent plasma, labelling and records keeping for donated convalescent plasma and regarding treatments ([@bib47]).

5.6. Pluristems allogeneic placental expanded cell therapy {#sec5.6}
----------------------------------------------------------

Placenta expanded cells are obtained from the placenta and are designed in such a way that theycan be administered to the patients without tissue or genetic matching. The main function of these cells is to release biomolecules such as growth factors, cytokines and chemokines. These cells act in a endocrine and paracrine manner and help the body to stimulate its defense mechanism and promote healing (<https://www.pluristem.com/placental-expanded-plx-products/>). The Israel biotech company, Pluristem Therapeutics Inc. reported that the patients [@bib157] had SARS-CoV-2 and were at a higher risk of death due to respiratory collapse and multiorgan failiure such as kidney and heart failure recovered after receiving this therapy. This happens due to the immunomodulatory effect of the pluripotent plasma cells (PLX). During treatment the 15 mL doses of PLX cells is administered to patients by intramuscular route ([@bib150]).

5.7. Miscellaneous treatment strategies {#sec5.7}
---------------------------------------

Melatonin is a N-acetyl-5-methoxytryptamine and having many health benefits such as remission from sleeping disorders, viral infections, delirium, respiratory disease and atherosclerosis ([@bib126]). Recent studies on COVID-19 revealed that the main cause of COVID-19 pathology is exaggerated immune response, oxidation and inflammation. All these factors lead to cytokine storm and give rise to Acute Respiratory Distress Syndrome (ARDS) and often death. [@bib162], described the anti-inflammatory, immunomodulatory and adjuvant effects of melatonin against SARS-CoV-2. Melatonin showed anti-inflammatory action by acting on sirtuin-1 (SIRT1) and nuclear factor kappa-B (NF-κB) pathways. Melatonin resulted in inhibition of high mobility group boxechromosomal protein1 (HMGB1) and led to downregulation of the polarization of macrophages. Melatonin\'s action on NF-κB resulted in inhibition of pro-oxidative and pro-inflammatory response. The immunomodulatory action of melatonin is due to maturation and proliferation of natural killer cells, B and T lymphocytes, monocytes and granulocytes in bone marrow and other tissues ([@bib84]; [@bib162]).

Miscellaneous antibodies, cell-based therapies and RNA based therapies which are beingused now a days to mitigate effect of COVID-19 and are under preclinical and clinical trials are depicted in [Table 7](#tbl7){ref-type="table"} .Table 7List of various treatments currently used against COVID-19.Table 7Sr. No.Type of Product -- TreatmentDeveloper/ResearcherDevelopment stageAnticipated Next Steps TimingReferences**Antibodies based treatment against COVID-19**1.H-IGOctapharm and Takeda Pharmaceutical Co.Pre-clinicalThe Phase 1 trials will begin in end of the spring([@bib122])\
([@bib159])\
([@bib120])2.VIR-7831 and VIR-7832GSK/Vir Biotech/SamsungPre-clinicalThe Phase 2 trials will begin in the month of july and september([@bib63])3.Thymosin; PD-1 blocking antibodyNumerous trials with Chinese research sponsorsClinicalThe Phase 2 of clinical trial will end on April 30, 2020([@bib14])4.Gimsilumab,Roivant SciencesClinicalThe phase 2 Study begins from April 2020([@bib131])5.SiltuximabEUSA PharmaClinicalInterim of April 2020([@bib43])6.SAB-185SAb BiotherapeuticsPre-clinicalPhase 1 starts early summer 2020([@bib134])7.SolirisAlexionClinicalThe phase 2 Study begins from April 2020([@bib6])8.rCIGGigaGenPre-clinical--([@bib50])9IlarisNovartisClinical--([@bib127])10.UltomirisAlexion PharmaceuticalsClinicalThe phase 2 will be begin in the month of May 2020([@bib25])11.COVID-EIGEmergent BioSolutionsPre-clinicalThe phase 2 will be begin in the month of August 2020([@bib63])12.OctagamOctapharmaClinical--([@bib24])**Cell based therapies used against COVID-19**1Mesenchymal stem cellsNumerous trials with global research sponsorsClinical--([@bib14])2.Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)Celltex----([@bib17]3.RyoncilMesoblastPre-clinical--([@bib51])4.MultiStem, bone marrow stem cellsAthersys/The University of Texas Health Science Center at HoustonClinicalPhase 2/3 trial to start 2Q 2020([@bib16])\
([@bib22])5Allogeneic T-cell therapiesBaylor College of Medicine/AlloVirPre-clinical--([@bib98])6CYNK-001, allogeneic, natural killer cell therapyCelularityClinicalThe phase 1/2 will be begin([@bib125])7CAP-1002, allogenic cardiosphere-derived cellCapricor Inc.----([@bib64])8haNK, natural killer cellsImmunityBio/NantKwestPre-clinical--([@bib23])**RNA based treatment for COVID-19**1.RNAi - testing 150 RNAisSirnaomicsPre-clinical--([@bib109])2.siRNA candidatesAlnylam Pharmaceuticals/Vir BiotechPre-clinical--([@bib21])3.Ampligen; (rintatolimod)AIM ImmunoTech/National Institute of Infectious Diseases in JapanPre-clinical--(<https://finance.yahoo.com/news/aim-immunotech-drug-ampligen-tested-103000673.html>)4.OT-101, a TGF-Beta antisense drug candidateMateon TherapeuticsClinical--([@bib35])5.Inhaled mRNANeurimmune/EthrisPre-clinicalPhase 1 to start Q4 2020([https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19](http://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19){#intref0550})

6. Conclusion and future perspective {#sec6}
====================================

The worldwide spread of COVID-19 has become a big challenge to control. It has already been declared as pandemic with more than 10 922 324 peoples affected across 195 countries till July 4^th^ 2020. An aggressive approach is required to take care of critically compromised patients in addition to sincere efforts to stop the transmission of disease. Currently many government agencies and [@bib115] companies are working towards development of effective medicines and vaccines. Also, the available treatment strategies have been adopted to benefit the affected people, however, major step still remains to stop the transmission and alleviate the symptoms of affected people. Use of hydroxychloroquine as well as antiviral drugs are found effective against COVID-19, however, detailed clinical studies are required. Some biotechnology-basedtechniques such as antibodies, cell and RNA based therapies have also been found to be very effective. It is expected that dexamethasone could bring some hope to treat this disease.However, it will be too early to give conclusive remarks on the currently available treatments since more evidence-based data is required to be generated. Government agencies are working on their part; however, a coordinated effort is needed globally to help prepare the healthcare framework cope up with the unprecedented challenge of COVID-19.
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